Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Net Income towards Common Stockholders (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with -$5.4 million as the latest value for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 74.8% year-over-year to -$5.4 million; the TTM value through Dec 2025 reached $6.0 million, up 112.39%, while the annual FY2025 figure was $6.9 million, 112.56% up from the prior year.
  • Net Income towards Common Stockholders hit -$5.4 million in Q4 2025 for Traws Pharma, down from -$3.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $15.1 million in Q1 2025 and bottomed at -$21.4 million in Q4 2024.
  • Average Net Income towards Common Stockholders over 5 years is -$5.0 million, with a median of -$4.5 million recorded in 2023.
  • Year-over-year, Net Income towards Common Stockholders tumbled 380.03% in 2024 and then soared 402.69% in 2025.
  • Traws Pharma's Net Income towards Common Stockholders stood at -$3.8 million in 2021, then tumbled by 52.38% to -$5.7 million in 2022, then grew by 22.18% to -$4.5 million in 2023, then crashed by 380.03% to -$21.4 million in 2024, then skyrocketed by 74.8% to -$5.4 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$5.4 million, -$3.0 million, and -$625000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.